Loading…
Entrada Therapeutics, Inc. is projected to rise to $7.63 by 2027, a +10% move from its current price of $6.92. TRDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $6.69 | $6.92 | $7.17 | +0.04% |
| Jul 15 | $6.60 | $6.93 | $7.27 | +0.09% |
| Jul 16 | $6.53 | $6.93 | $7.35 | +0.13% |
| Jul 17 | $6.47 | $6.93 | $7.43 | +0.18% |
| Jul 18 | $6.42 | $6.94 | $7.49 | +0.22% |
| Jul 19 | $6.38 | $6.94 | $7.55 | +0.26% |
| Jul 20 | $6.34 | $6.94 | $7.60 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.34 | $6.94 | $7.60 | +0.31% |
| Week 2 | $6.12 | $6.96 | $7.92 | +0.62% |
| Week 3 | $5.97 | $6.98 | $8.18 | +0.93% |
| Week 4 | $5.84 | $7.01 | $8.40 | +1.24% |
| Week 5 | $5.73 | $7.03 | $8.61 | +1.55% |
| Week 6 | $5.64 | $7.05 | $8.81 | +1.86% |
| Week 7 | $5.56 | $7.07 | $8.99 | +2.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Endosomal Escape Vehicle supports development of therapeutic candidates, with a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Its preclinical products include ENTR-601-44; ENTR-601-45; and VX-670.
The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Entrada Therapeutics, Inc. trades in the Healthcare sector and carries a current price of $6.92 with a market capitalization of $268.64M. It is ranked 3577 by market cap.
The price outlook from the forecast shows a rising path through 2030 and beyond, with average prices advancing from 2026 to 2050: 2026 avg $6.92; 2027 avg $7.64; 2028 avg $8.67; 2029 avg $10.28; 2030 avg $12.95; 2031 avg $15.70; 2032 avg $15.53; 2033 avg $16.41; 2034 avg $18.57; 2035 avg $18.17; 2040 avg $29.41; 2050 avg $71.62. The maximum forecast by 2050 is $145.14 and the minimums for notable milestones include $9.17 (2030) and $17.01 (2040).
The forecasted ROI rises along with the price: 2030 ROI 87.1; 2040 ROI 325.1; 2050 ROI 934.9, with a broader pattern of rising implied value over time.
A major floor 26.2% below — a decisive break under it would weaken the trend.
The nearest floor, 13.7% below — buyers have tended to step in here.
The nearest ceiling, 11.8% above — a clean break opens room to run.
A major ceiling 131.6% above — clearing it would confirm fresh momentum.
Key TRDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.32 | Sell | $7.26 | Sell |
| MA 10 | $7.47 | Sell | $7.31 | Sell |
| MA 20 | $7.17 | Sell | $7.28 | Sell |
| MA 50 | $7.80 | Sell | $8.05 | Sell |
| MA 100 | $10.20 | Sell | $9.01 | Sell |
| MA 200 | $9.59 | Sell | $9.46 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.25 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -46.02 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -4.42 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | 0.39 | Buy |
| Ultimate (7,14,28) | 39.55 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 7.19 | Sell |
| ADX (14) | 12.50 | Neutral |
| ATR (14) | 0.26 | Info |
The 30-day technical picture is bullish with a sentiment labeled BULLISH. The RSI14 is 40, and the 50-day simple moving average is $7.80 while the 200-day simple moving average is $9.59. Near-term support sits at $5.97 and resistance at $7.74. The last 30-day range trades between $5.52 and $8.68.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.65 | $6.92 | $9.80 | 0% | Neutral | |
| $5.93 | $7.63 | $10.48 | +10% | Neutral | |
| $6.50 | $8.67 | $12.45 | +25% | Bullish | |
| $7.47 | $10.28 | $15.28 | +49% | Bullish | |
| $9.15 | $12.93 | $19.79 | +87% | Bullish | |
| $10.85 | $15.71 | $24.66 | +127% | Bullish | |
| $10.48 | $15.53 | $24.94 | +124% | Bullish | |
| $10.82 | $16.39 | $26.86 | +137% | Bullish | |
| $12.02 | $18.58 | $31.02 | +168% | Bullish | |
| $11.53 | $18.18 | $30.89 | +163% | Bullish | |
| $17.01 | $29.41 | $53.72 | +325% | Bullish | |
| $35.18 | $71.67 | $145.25 | +936% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.65 | $6.92 | $8.55 | +0.00% |
| August 2026 | $6.02 | $7.15 | $8.76 | +3.31% |
| September 2026 | $6.01 | $7.20 | $8.95 | +0.75% |
| October 2026 | $6.30 | $7.62 | $9.57 | +5.77% |
| November 2026 | $6.45 | $7.84 | $9.95 | +2.91% |
| December 2026 | $6.25 | $7.65 | $9.80 | -2.42% |
Click any year to see its month-by-month TRDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Entrada Therapeutics, Inc.'s 2026 outlook centres on $6.92, within a $5.65 to $9.80 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TRDA could reach as high as $10.48, with a base case around $7.63 and support toward $5.93 — roughly +10% from $6.92. A consolidation phase looks the most probable path here.
Expect TRDA to range from $6.50 to $12.45 through 2028. The $8.67 average target implies a +25% move from current prices. That is up +14% on the projected 2027 average. Momentum favours further upside here.
The TRDA price prediction for 2029 points to an average of $10.28 (low $7.47, high $15.28) — a potential gain of +49% on today's $6.92. Buyers look set to stay in control over this stretch.
In 2030, TRDA is projected to trade between $9.15 and $19.79, averaging $12.93 — a potential gain of +87% from today's $6.92. That is up +26% on the projected 2029 average. Momentum favours further upside here.
Entrada Therapeutics, Inc.'s 2031 outlook centres on $15.71, within a $10.85 to $24.66 range. That is up +22% on the projected 2030 average. That marks a +127% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TRDA could reach as high as $24.94, with a base case around $15.53 and support toward $10.48 — roughly +124% from $6.92. Momentum favours further upside here.
Expect TRDA to range from $10.82 to $26.86 through 2033. The $16.39 average target implies a +137% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TRDA price prediction for 2034 points to an average of $18.58 (low $12.02, high $31.02) — a potential gain of +168% on today's $6.92. Momentum favours further upside here.
In 2035, TRDA is projected to trade between $11.53 and $30.89, averaging $18.18 — a potential gain of +163% from today's $6.92. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Entrada Therapeutics, Inc.'s 2040 outlook centres on $29.41, within a $17.01 to $53.72 range. That is up +62% on the projected 2035 average. That marks a +325% change versus current levels. Momentum favours further upside here.
By 2050, TRDA could reach as high as $145.25, with a base case around $71.67 and support toward $35.18 — roughly +936% from $6.92. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRDA today (≈ 144.508671 TRDA) could be worth
$10,357.24
+$9,357.24 (+936%) by 2050 · US Dollar
Based on the average projected TRDA price of $71.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRDAwould be worth at today's price.
$1,000 invested in TRDA on Jul 10, 2025 (≈ 147.928989 TRDA) would be worth
$1,023.67
+$23.67 (+2.4%) today · 1.02× · US Dollar
Based on a TRDA entry price of $6.76 vs. today's $6.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.72 | $896.37 | -10.4% |
| 1 month ago | $5.97 | $1,159.13 | +15.9% |
| 3 months ago | $13.5 | $512.59 | -48.7% |
| 6 months ago | $9.95 | $695.48 | -30.5% |
| 1 year ago | $6.76 | $1,023.67 | +2.4% |
| All time (4.7y) ago | $23.95 | $288.94 | -71.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRDA forecast.
Our base-case forecast reaches $14.00 around 2031.
Implied market cap at $14.00: $543.49M
The multi-year forecast shows a bullish trajectory with notable upside. The 2030 forecast shows an average price of $12.95 and a minimum of $9.17 with a maximum of $19.82, and a forecasted ROI of 87.1. The 2040 forecast shows an average price of $29.41 with a minimum of $17.01 and a maximum of $53.72, and a forecasted ROI of 325.1.
The 2050 forecast shows an average price of $71.62 with a minimum of $35.15 and a maximum of $145.14, and a forecasted ROI of 934.9.
These figures imply substantial upside but are not guarantees and are subject to market conditions and company progress.
Tap a question to reveal the answer.
2030 avg $12.95; min $9.17; max $19.82; ROI 87.1; sentiment BULLISH.
Forecasts show rising averages with bullish sentiment and ROI increasing to 87.1 by 2030, 325.1 by 2040, and 934.9 by 2050, but these are estimates and not guarantees.
Yes—the max forecast for 2050 is $145.14, with 2050 average of $71.62 and up to $145.14.
Current price $6.92; market cap $268.64M; rank 3577; sector Healthcare.
30-day range low $5.52 and high $8.68.
Entrada Therapeutics, Inc. Community Discussion
0Share your Entrada Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.